Pacer Advisors
ACHN

Pacer Advisors’s Achillion Pharmaceuticals ACHN Stock Holding History

Pacer Advisors’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-13,474
Closed -$50K – 1160
2018
Q3 		$50K Buy
+13,474
New +$40.2K ﹤0.01% 1142
2018
Q1 		– Sell
-3,132
Closed -$9K – 1175
2017
Q4 		$9K Buy
+3,132
New +$11.4K ﹤0.01% 1149

Other funds holding ACHN

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Pacer Advisors's ACHN Position: Q4 2018 in Review

Pacer Advisors sold out of Achillion Pharmaceuticals (ACHN) in Q4 2018, closing a stake of 13,474 shares — an estimated $50K sold.

Pacer Advisors first reported a position in ACHN in Q4 2017 and held it in 2 quarters. The position peaked at $50K in Q3 2018. 121 funds tracked by Wall St. Rank hold ACHN as of Q4 2018.

  • Pacer Advisors reported no remaining Achillion Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
  • Pacer Advisors sold 13,474 Achillion Pharmaceuticals shares in Q4 2018, an estimated $50K.
  • Pacer Advisors first reported a position in Achillion Pharmaceuticals in Q4 2017 and held it in 2 quarters.
  • Pacer Advisors's Achillion Pharmaceuticals position peaked at $50K in Q3 2018.
  • 121 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q4 2018.

Based on Pacer Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.